---
title: "Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295211168.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-08-07T08:43:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295211168.md)
  - [en](https://longbridge.com/en/news/295211168.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295211168.md)
generator: "portal-rs"
---

# Mediar and Ono Pharmaceutical to develop fibro-inflammatory treatments

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [4528.JP](https://longbridge.com/en/quote/4528.JP.md)
- [OPHLY.US](https://longbridge.com/en/quote/OPHLY.US.md)

## Related News & Research

- [Ono Pharma partners with Mediar Therapeutics on antibody drugs for fibro-inflammatory diseases](https://longbridge.com/en/news/295097879.md)
- [Firefox for iOS Gets Built-In Ad Blocker](https://longbridge.com/en/news/297656638.md)
- ["Oreogate" on Instagram went viral. But was it all a fake ad for an AI company?](https://longbridge.com/en/news/297357874.md)
- [FDA approves Priovant’s rare autoimmune therapy Lisraya in indication first](https://longbridge.com/en/news/297336275.md)
- [SK inks $795m Biohaven epilepsy deal, entering potassium channel opener race](https://longbridge.com/en/news/297220838.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**